We are presenting the results of our research at the ECC in Amsterdam

Celon Pharma S.A. will participate in The European Cancer Congress 2013, which will be held in Amsterdam, the Netherlands. We will be presenting two posters at a session which is taking place on 29 September 2013: “Epithelial-mesenchymal transition confers resistance to FGFR inhibitors in gastric cancer cell line” and “Design and development of active and selective FGFR kinase inhibitor CPL-043 as potential anticancer targeted therapy”.